$BICX

BioCorRx Inc.

BioCorRx is a holding company whose subsidiary develops and provides addiction treatment solutions for substance use and related disorders. Its Beat Addiction Recovery program typically combines proprietary Cognitive Behavioral Therapy modules and peer support through a mobile app with medication prescribed by an independent physician. The company also offers the UnCraveRx weight loss management program, which provides access to wellness specialists, including nutritionists, fitness experts and behavioral support. BioCorRx makes these programs available to healthcare providers, and it has license and distribution agreements with third parties for addiction treatment centers and programs. Through its majority-owned BioCorRx Pharmaceuticals subsidiary, BioCorRx develops BICX104, a long-acting naltrexone pellet for opioid use disorder and methamphetamine use disorder. The subsidiary also acquired assets related to Lucemyra, an FDA-approved medication for opioid withdrawal, and generates supply and distribution sales from Lucemyra products and distribution licenses. BioCorRx is headquartered in Anaheim, California.

1
0
0

No SEC Form 4 filings for $BICX in the last 30 days.

See all $BICX insider activity →

BioCorRx Inc. (BICX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

BioCorRx Inc. (BICX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Director On August 31, 2026, Kate Beebe DeVarney, Ph.D. submitted her resignation from her position as a mem

BICX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning BICX (BioCorRx Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent BICX coverage spans financial news and corporate actions.

What's driving BICX

  • Execution progress on LUCEMYRA transition and added IP plus a Phase 1 start can support sentiment, but near-term trading impact is likely limited without quantified results.

    tradingview.com · Nov 17, 2026

  • Board change may affect governance perception but no immediate financial impact.

    SEC EDGAR 8-K · Sep 4, 2026

AlphAI scores every news story that mentions BICX with an AI model for sentiment and relevance, and aggregates insider trades from BioCorRx Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BICX

Score
$BICXLowExec change· resigned

BioCorRx Inc. (BICX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

BioCorRx Inc. (BICX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Director On August 31, 2026, Kate Beebe DeVarney, Ph.D. submitted her resignation from her position as a mem

Related tickers